The new chair of the ACR’s Pediatric Rheumatology Committee, Ekemini A. Ogbu, MD, MSc, FAAP, describes how helping children and families navigate complex care brings a sense of fulfillment, purpose and “just joy.”
How RheumPAC Is Supporting You in Uncertain Times
As the new administration enacts policies that impact you and the care you provide to your patients, RheumPAC is working to inform key lawmakers of the downstream effects of these unilateral actions. Learn more about RheumPAC’s role in the ACR’s advocacy efforts.
FDA Approval Sought for 2 Pediatric Indications for Guselkumab
The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
Rheumatologist Elected to Key AMA Committee That Helps CMS Set Medicare Reimbursements
Luke Barré, MD, MPH, RhMSUS, has been elected to the American Medical Association’s Relative Value Update Committee. He is the second rheumatologist to hold the seat in recent years and will ensure representation of the specialty during valuation of physician services.
ACR Comments on Proposed Medicare Advantage Changes
In response to proposed changes to the Medicare Advantage and prescription drug programs for contract year 2026, the ACR submitted comments on the provisions related to the Inflation Reduction Act, prior authorization and the influence that pharmacy benefit managers have on the placement of biosimilars on formularies.
The HHS Seeks Comments on Proposed Changes to HIPAA Security Rule
The proposed changes aim to address modern breach and cybersecurity risks to electronic protected health information and common deficiencies observed by the HHS in Security Rule compliance investigations.
The ACR Commends Legislation to Address Harmful Medicare Payment Cuts to Physicians
The Medicare Patient Access and Practice Stabilization Act of 2025 would fully offset the harmful 2.8% cut in the MPFS and include an additional 2% payment update to physician services furnished after April 1.
Cancer & RA Drugs: Are Some Drugs Riskier than Others?
Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.
Answering the Call: Anisha Dua, MD, MPH, Looks Ahead to New Role on Committee on Training
Building on her experiences in her practice and through the ACR, this rheumatology leader and educator is eager to advance the work of the COT.
Through Thick & Thin: Updates in Scleroderma
Pulmonary hypertension and Raynaud’s phenomenon are just some of the symptoms patients with systemic sclerosis (SSc) may experience. Here are insights into the diagnosis and management of SSc.
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 325
- Next Page »